Driehaus Capital GRDN Position
ActiveDriehaus Capital trimmed their position in Guardian Pharmacy Services, Inc. (GRDN) in Q4 2025, holding $15.2M worth of shares across 506,475 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
Short interest stands at 11.8% of float with 5.0 days to cover, indicating significant bearish positioning against Driehaus's long thesis.
About Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
Full company profile →Short Interest
11.8%
5.0 days to cover
Driehaus Capital GRDN Position History
Frequently Asked Questions
Does Driehaus Capital own GRDN?
Yes. As of Q4 2025, Driehaus Capital holds 506,475 shares of Guardian Pharmacy Services, Inc. (GRDN) valued at $15.2M. This data comes from their SEC 13F filing.
How many hedge funds own GRDN?
1 specialist biotech hedge fund currently holds GRDN. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy GRDN?
Driehaus Capital's position in GRDN was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's GRDN position increasing or decreasing?
Driehaus Capital trimmed their GRDN position in the most recent quarter, reducing by 17,460 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GRDNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →